Article
https://doi.org/10.1038/s41467-023-38428-2
RagD auto-activating mutations impair
MiT/TFE activity in kidney tubulopathy
and cardiomyopathy syndrome
Received: 2 June 2022
1234567890():,;
1234567890():,;
Accepted: 3 May 2023
Check for updates
Irene Sambri 1,2,14, Marco Ferniani 1,2,14, Giulia Campostrini 3,
Marialuisa Testa1, Viviana Meraviglia 3, Mariana E. G. de Araujo 4,
Ladislav Dokládal5, Claudia Vilardo 1, Jlenia Monfregola1, Nicolina Zampelli1,
Francesca Del Vecchio Blanco 6, Annalaura Torella1,6, Carolina Ruosi7,
Simona Fecarotta2, Giancarlo Parenti1,2, Leopoldo Staiano 1,8,
Milena Bellin 3,9,10, Lukas A. Huber 4, Claudio De Virgilio 5,
Francesco Trepiccione7,11, Vincenzo Nigro1,6 & Andrea Ballabio 1,2,12,13
Heterozygous mutations in the gene encoding RagD GTPase were shown to
cause a novel autosomal dominant condition characterized by kidney
tubulopathy and cardiomyopathy. We previously demonstrated that RagD,
and its paralogue RagC, mediate a non-canonical mTORC1 signaling pathway that inhibits the activity of TFEB and TFE3, transcription factors of the
MiT/TFE family and master regulators of lysosomal biogenesis and autophagy. Here we show that RagD mutations causing kidney tubulopathy and
cardiomyopathy are “auto- activating”, even in the absence of Folliculin, the
GAP responsible for RagC/D activation, and cause constitutive phosphorylation of TFEB and TFE3 by mTORC1, without affecting the phosphorylation of “canonical” mTORC1 substrates, such as S6K. By using HeLa and HK2 cell lines, human induced pluripotent stem cell-derived cardiomyocytes
and patient-derived primary fibroblasts, we show that RRAGD autoactivating mutations lead to inhibition of TFEB and TFE3 nuclear translocation and transcriptional activity, which impairs the response to lysosomal
and mitochondrial injury. These data suggest that inhibition of MiT/TFE
factors plays a key role in kidney tubulopathy and cardiomyopathy
syndrome.
Inherited kidney tubulopathies are kidney homeostasis disorders
caused by dysfunctional proteins involved, either directly or indirectly, in the tubular transport of water and solutes. This group of
diseases is highly heterogeneous, both genetically and clinically1,2. A
recent study described nine families with an autosomal dominant
disease entity characterized by the association of kidney tubulopathy and hypomagnesemia with severe dilated cardiomyopathy3.
All affected individuals in these families carried mutations in the
RRAGD gene (also named RAGD), encoding the GTPase RagD3. Rag
A full list of affiliations appears at the end of the paper.
Nature Communications | (2023)14:2775
GTPases, heterodimeric complexes formed by RagA or B bound to
RagC or D, are involved in the activation of the mechanistic Target
Of Rapamycin Complex 1 (mTORC1) by mediating its recruitment to
the lysosomal surface4–8. To activate mTORC1, RagA/B must be in
the GTP-bound state, whereas the nucleotide-binding state of RagC/
D does not play a major role in mTORC1-mediated phosphorylation
of “canonical” substrates, such as S6K and 4E-BP14–9. By contrast, we
showed recently that GDP-binding of RagC/D, which is driven by the
GTPase-activating protein (GAP) folliculin (FLCN), plays a crucial
e-mail: ballabio@tigem.it
1
Article
https://doi.org/10.1038/s41467-023-38428-2
role in mTORC1-mediated selective phosphorylation and cytoplasmic retention of the Transcription Factors EB and E3 (TFEB
and TFE3)4, master controllers of lysosomal biogenesis and
autophagy10,11. Consistent with this, loss of function of folliculin
(FLCN) leads to constitutive nuclear localization and activation of
TFEB and TFE3, without affecting the activity of mTORC1 on other
substrates such as S6K4,12,13. This mTORC1 substrate-specific pathway was named “non-canonical mTORC1 signaling”14. A recent study
determined the Cryo-EM structure of the mTORC1-TFEB-RagRagulator complex supporting the presence of both “canonical”
and “non-canonical” branches of the pathway15. Here we describe a
new family with kidney tubulopathy and cardiomyopathy syndrome
carrying a novel RRAGD mutation (P88L) that, similarly to previously described mutations3, impairs RagD ability to bind GTP,
leading to a constitutive active protein. This leads to constitutive
phosphorylation of TFEB and TFE3, thus inhibiting their nuclear
translocation both in FLCN KO and in wild-type cells subjected to
lysosomal or mitochondrial stress conditions. These observations
suggest that TFEB and TFE3 inhibition drives kidney tubulopathy
a
and dilated cardiomyopathy in patients with RagD auto-activating
mutations.
Results
Identification of a novel RRAGD mutation
We identified a large family affected by hypomagnesemia, mild
hypokalemia and severe medullary nephrocalcinosis associated
with heart disease including arrhythmias, valvulopathies, myocardial infarction and dilated cardiomyopathy. Clinical and laboratory data of this family are reported in Fig. 1a, b, Supplementary
Table 1 and in the Supplementary data section. We collected data
from a wide range of ages (from 5 to 62 y/o) covering three generations (Fig. 1c) and performed whole-exome sequencing analysis
which revealed that affected members carried a novel c.263 C > T
(p.P88L) mutation in the RRAGD gene. Similarly to previously
described families with kidney tubulopathy and cardiomyopathy3,
the mutated amino acid, proline 88, is highly conserved and located
within the RagD GTP-binding motif at the N-terminus of the
protein16 (Fig. 1d).
b
c
I.
1
II.
1
3
2
*#
Het
2
4
5
7
6
Het
*#
8
III.
1
#
Het
2
3#
No Mut
4
5#
Het
7
6
8
10
9
11
11
12
#
No Mut
13 # 14
No Mut
15
16
IV.
1 # 2 #
No Mut Het
3
4
5
7
6
8
Het *#
9
* Whole exome sequencing (WES)
# Sanger sequencing
d
Pro88LeuThr97Pro
Ser76Leu
Ser76Trp
Pro119Leu
Pro119Arg
Ile221Lys
CTD
G1
G2
G3
G4
G5
RagD GTP-binding motif
Fig. 1 | A new RRAGD mutation associated with tubulopathy and cardiomyopathy. a Representative image of left ventricle ultrasound from patient II.1,
showing ventricle dilatation (Left ventricular end-diastolic diameter 62 mm and
area 42,02 cm2). b Representative image of kidney ultrasound of patient III.15;
showing severe medullary nephrocalcinosis. c Pedigree of the family and indication
of the individuals carrying the p.P88L RRAGD mutation. Filled symbols represent
Nature Communications | (2023)14:2775
affected individuals carrying the mutation and symptomatic for kidney and/or
heart abnormalities. d Domain organization of RagD protein with GTP-binding
motifs reported in light gray (G1–G5). Pathogenic mutations affecting RagD protein
stability, binding to GTP, and Mg2+ coordination are indicated in orange, green, and
magenta, respectively.
2
Article
In silico modeling and in vitro assays reveal a gain of function of
RagD mutations
To evaluate the molecular consequences of the P88L mutation, as well
as of the previously described RRAGD mutations3, we predicted computationally if these would alter protein stability and/or binding to
either magnesium or the phosphate (Supplementary Tables 2 and 3). In
addition, we generated in silico models of the mutations (Supplementary Fig. 1a–d). These analyses indicated that S76L and S76W
mutations are likely to affect magnesium coordination (Supplementary Fig. 1b), which is required for GTP binding17, T97P may directly
affect GTP binding (Supplementary Fig. 1c), whereas the remaining
mutations (P88L, P119L, P119R, and I221K) were predicted to decrease
protein stability (Supplementary Fig. 1d). Switch I and Switch II of the
Rag GTPases are likely to undergo major conformation changes during
the activation cycle. Because of the lack of information on the RagDGDP structure, we analyzed the corresponding residues in RagC to
determine whether the effects of mutations on the stability of RagD
were associated with the GTP- bound state (Supplementary Table 2).
Interestingly, the disease-causing mutations did not seem to alter
RagC/D stability in the nucleotide-free or GDP-bound states. Thus, all
these mutations are predicted to affect, either directly or indirectly,
GTP loading. To test this prediction, we generated recombinant proteins for the WT and mutated RagD versions and tested them for GTPbinding and GTPase activity assays (see “Methods”). WT RagD bound
GTP in a concentration-dependent manner, whereas all RagD mutants
were impaired in GTP binding, irrespective of the protein concentration (Supplementary Fig. 1e, f). Moreover, all the disease-associated
mutations impaired the GTP hydrolysis activity of RagD (Supplementary Fig. 1g, h). These data indicate that RagD mutants are unable to
bind GTP and are thus in a nucleotide-free state or a GDP-loaded state,
which are both active conformations, indicating that these are autoactivating mutations.
In a previous study, we showed that only active (i.e., GDP-loaded)
RagC/D physically interact with TFEB, thus mediating a novel substrate
recruitment mechanism that enables mTORC1 to phosphorylate
TFEB4,14. Indeed, RagC/D interaction with TFEB is lost in FLCN KO cells
due to constitutive inactivation of RagC/D4,14. To test if the RagD autoactivating mutations identified in Schlingmann et al.3 and in the present study were able to induce the interaction with TFEB in a FLCN
independent-manner, we performed co-immunoprecipitation (Co-IP)
analysis in HeLa FLCN KO cells transiently expressing TFEB and Rag
GTPases (RagD WT or RagD mutants in combination with RagA WT or
RagB WT). The results showed that RagD disease-associated mutations, unlike RagD wild type, rescued the interaction between RagD
and exogenous TFEB in FLCN KO cells (Fig. 2a and Supplementary
Fig. 1i, j). A similar effect was observed when probing the interaction
between endogenous TFEB and transiently expressed RagD mutants
(Fig. 2b). Interestingly, this interaction occurred in an mTORC1independent manner (also in the presence of Torin) (Fig. 2b). Overall,
these mutations cause RagD auto-activation with no requirement of
FLCN GAP activity.
RagD auto-activating mutants inhibit TFEB/3 activity
Consistent with their ability to induce RagD-TFEB interaction in FLCN
KO cells, we found that mutant RagD cDNAs rescued mTORC1mediated TFEB phosphorylation in HeLa FLCN KO cells, as detected
both by the analysis of a molecular weight shift of TFEB (Fig. 2c and
Supplementary Fig. 2a) and using a phospho-antibody against TFEB
(Serine 211)18 (Supplementary Fig. 2c, d). As expected, Torin treatment
prevented this effect (Fig. 2c), indicating that RagD mutations induce
TFEB phosphorylation by mTORC1. Similar results were obtained using
dermal fibroblasts generated from a patient carrying the RRAGD P88L
mutation (Fig. 2d). Importantly, the expression of RagD mutants had
no effect on the phosphorylation of the canonical mTORC1 substrate
S6K (Fig. 2c, d and Supplementary Fig. 2a, b). We then evaluated the
Nature Communications | (2023)14:2775
https://doi.org/10.1038/s41467-023-38428-2
lysosomal recruitment-detachment of mTORC1 in the presence of
RagD mutants either under basal or amino acid starvation conditions.
HeLa cells expressing WT or mutant RagD showed the expected
detachment of mTORC1 from lysosomes in amino acid starved cells
(Supplementary Fig. 2e, f). Similar results were obtained in patientderived fibroblasts carrying the RRAGD P88L mutation (Supplementary Fig. 2g). In contrast, HeLa cells expressing RagA Q66L, a mutated
version of RagA, that is known to promote mTORC1 lysosomal
recruitment and activity towards S6K19 during amino acid starvation,
showed constitutive mTORC1 lysosomal localization (Supplementary
Fig. 2e, f). Taken together, these results demonstrate that RagD
mutations promote non-canonical mTORC1 signaling14, leading to
TFEB phosphorylation without affecting mTORC1 lysosomal localization and its activity towards canonical mTORC1 substrates. Interestingly, the expression of RagD mutants leads to an increase of both
exogenous and endogenous TFEB protein levels in HeLa FLCN KO cells
(Fig. 2a, b), possibly by enhancing TFEB stability, through an increased
interaction with 14-3-3, only in the presence of RagD mutants (Supplementary Fig. 2h). Otherwise, we do not appreciate the same
increase of TFEB protein levels in fibroblast derived-patient carrying
the P88L heterozygous mutation, probably due to the different conditions between the two cell lines.
Based on these observations, we tested whether the effect of
RagD mutants on TFEB phosphorylation would also affect the subcellular localization of TFEB. Expression of RagD cDNAs carrying
disease-causing mutations P88L, S76L, T97P, P119L, and I221K in HeLa
FLCN KO cells, promoted TFEB cytoplasmic re-localization (Fig. 2e, f
and Supplementary Fig. 3a). Similar results were obtained in HK-2 FLCN
KO cells carrying an inducible TFEB-GFP system (Fig. 2g, h and Supplementary Fig. 3b), as well as in patient-derived fibroblasts carrying
the RRAGD P88L mutation (Fig. 2i, j). As expected, TFE3 behaved like
TFEB, consistent with the evidence that the nucleo-cytoplasmic shuttling of these transcription factors is regulated by the same
mechanisms20–23 (Supplementary Fig. 3c). Finally, to monitor whether
RagD mutant-induced TFEB cytoplasmic re-localization resulted
in inactivation of its transcriptional activity, we generated a new MiTTFE transcriptional reporter by placing the NUC-mCherry fluorophore
downstream of the promoter of GPNMB (GPNMBprom-NUC-mCherry),
a highly sensitive TFEB transcriptional target24,25. A HeLa FLCN KO cell
line stably expressing the GPNMBprom-NUC-mCherry reporter was
transiently transfected with HA-tagged RagD mutants. A significant
decrease of reporter activity was observed in the presence of RagD
mutants indicating that these mutations inhibit TFEB transcriptional
activity by inducing its cytoplasmic localization (Supplementary
Fig. 3d, e). Consistent with these data, Real Time-PCR analysis showed
marked reduction of the expression of TFEB target genes in HeLa FLCN
KO cells transfected with RagD mutants compared to cells transfected
with WT RagD (Supplementary Fig. 3f). Moreover, performing the
same experiment in TFEB/TFE3 knockdown cells, we confirmed that
the inhibition of the expression of target genes is correlated with the
expression of TFEB and TFE3 (Supplementary Fig. 3g). Together, these
data strongly suggest that RagD auto- activating mutations have a
strong impact on kidney tubulopathy and cardiomyopathy by inhibiting MiT-TFE nuclear translocation and activity.
RagD mutations affect TFEB localization and activity during
lysosomal and mitochondrial injury
Both TFEB and TFE3 are key regulators of the lysosomal-autophagic
pathway10,11,20,22,26, a crucial process that controls cellular homeostasis
and survival27, which is defective in several diseases28. TFEB is known to
promote intracellular clearance through its transcriptional control of
the lysosomal-autophagic pathway29. Indeed, TFEB overexpression
improves the phenotypes associated with various diseases characterized by autophagy defects, including kidney diseases and cardiac
hypertrophy29–31. Recently, it has been shown that treatments
3
Article
https://doi.org/10.1038/s41467-023-38428-2
c
HeLa FLCN KO
_____________________________
IP:FLAG
_____________
Input 1%
____________________
FLAG
95-
-HA-RagD
72-
-HA-RagA
72-
FLAG
95-
-HA-RagD
72-
+
+
S76L
+
WT
_
+
+
+
+
kDa
72-
HA
kDa
kDa
72-
S76L
+
+
WT
+
+
_
+
HeLa FLCN KO
_________________________
HA-RagD Empty
WT S77L
S76L _____
P88L P119L
_____ _____
_____ _____
_____
_ + _ + _ + _ + _ + _ +
Torin
Torin
_____________
P88L
+
+
HA-RagD
HA-RagA
-HA-RagA
43-
GAPDH
Input 1%
IP:HA
_________________________
_____________________
S77L
+
+
I211K
+
+
P88L
+
+
T97P
+
+
P119L
WT
HA-RagD
HA-RagA +
FLAG-TFEB +
S76L
HeLa FLCN KO
____________________________
empty
a
DMSO
_____________
P88L
b
TFEB
55TFEB
72-
7272-
p-S6K
43-
Actin
S6K
-HA-RagD
-HA-RagA
72-
72-
FED
AA STARV
REF
TFEB
RRAGD_P88L
Control
d
+
-
+
-
+
+
-
+
-
+
-HA-RagD
kDa
72-
-HA-RagA
55-
TFEB
43-
GAPDH
72-
p-S6K
72-
S6K
Actin
43-
TFEB
Lamp1
HA
TFEB
Lamp1
HA
TFEB
Lamp1
HA
TFEB
Lamp1
✱✱✱✱
2.5
✱✱✱
2.0
1.5
1.0
0.5
0.0
HA-RagD
g
P88L
f
S77L
HA-RagD-P88L
WT
HA-RagD-S77L
Hela FLCN KO
HA-RagD-WT
TFEB nuclear translocation
(nucleo/cyto intensity)
Human Fibroblast
e
i
TFEB
HA
Lamp1
TFEB
HA
Lamp1
TFEB
Lamp1
J
1
0
Lamp1
TFEB
TFEB
Lamp1
TFEB
TFEB nuclear traslocation
(Int nucl/cyt)
Control
RRAGD WT
RRAGD P88L
TFEB
TFEB
Lamp1
RRAGD_P88L
2
HA-RagD
AA STARV
FED
3
P88L
HA
✱✱✱
S77L
TFEB
Lamp1
✱✱✱
4
WT
TF EB nuclear translocation
(nucleo/cyto intensity)
HK-2 FLCN KO
h
**
2.5
**
**
ns.
2.0
1.5
1.0
0.5
0
Feeding
Lamp1
Lamp1
aminoacid
starvation
Human Fibroblast
Human Fibroblast
with the lysosomotropic compound l-leucyl-l-leucine methyl ester
(LLOMe) or with the TRPML1 agonist MK6-83 selectively inhibit the
phosphorylation of TFEB by mTORC1, thus promoting its nuclear
translocation, without affecting the phosphorylation of the canonical
mTORC1 substrates32,33. TFEB activation during lysosomal damage is
essential for the maintenance of lysosome homeostasis33. Remarkably,
Nature Communications | (2023)14:2775
in cells transfected with auto-activating RagD mutants, treatment with
LLOMe (Fig. 3a, b and Supplementary Fig. 4a, b) or with MK6-83
(Fig. 3d, e and Supplementary Fig. 4c, d) failed to induce the nuclear
translocation of TFEB, which was retained in the cytosol and phosphorylated by mTORC1 on S211 (Supplementary Fig. 4e). Furthermore,
neither of the treatments altered the phosphorylation of S6K, a
4
Article
https://doi.org/10.1038/s41467-023-38428-2
Fig. 2 | RagD mutations impair TFEB nuclear translocation.
a Immunoprecipitation performed in HeLa FLCN KO transfected with FLAG-TFEB
(bait) and HA-RagD WT or HA-RagD mutants (S76L, T97P, P119L, I221K, P88L, S77L)
and with equimolar amount of HA-RagA WT (n = 2 independent experiments).
b Immunoprecipitation performed in HeLa FLCN KO transfected with HA-RagD WT
or HA-RagD mutants (P88L and S76L) and with an equimolar amount of HA-RagA
WT to analyze the interaction with the endogenous TFEB. Cells were also treated
with Torin (n = 2 independent experiments). c Western blot of cell lysates of HeLa
FLCN KO cells transiently transfected with HA-RagD WT or HA-RagD mutants (S77L,
S76L, P88L, P119L) and treated with Torin. anti-TFEB, anti-phopho-S6K, anti-S6K,
and anti-actin antibodies were used (n = 3 independent experiments). d Western
blot representing TFEB molecular weight shift, phospho-S6K and total S6K in
human fibroblasts carrying the RRAGD P88L mutation and relative control fibroblasts. Cells were analyzed in normal feeding (FED), amino acid starved (AA STARV)
and amino acid replenished conditions (REF) (n = 2 independent experiments).
e Representative images of HeLa FLCN KO cells transiently transfected with HARagD-WT or HA-RagD mutants (S77L and P88L) and immunostained with anti-TFEB,
anti-LAMP1 and anti-HA antibodies. Scale bar, 10 μm. f Graph shows TFEB nuclear-
cytosolic ratio intensity in HeLa FLCN KO cells transiently transfected with HARagD-WT or HA-RagD mutants (S77L, P88L) (mean ± s.d. of n > 1000 cells from n = 3
independent experiments). Quantification performed using the Perkin-Elmer
Opera system (see “Methods”). Ordinary one-way ANOVA Tukey multiple comparison test (***p < 0.001, ****p < 0.0001). g HK-2 FLCN KO cells expressing TFEBGFP were transiently transfected with HA-RagD-WT or HA-RagD mutants (S77L and
P88L) and immunostained with anti-HA and anti-LAMP1 antibodies. Scale bar, 10
μm. h Graph shows TFEB nuclear-cytosolic ratio intensity in HK-2 FLCN KO TFEBGFP transiently transfected with HA-RagD-WT or HA-RagD mutants (S77L, P88L)
(mean ± s.d. of n > 1000 cells from n = 3 independent experiments). Quantification
performed as in (f). Ordinary one-way ANOVA Tukey multiple comparison test
(***p < 0.001). i Representative immunofluorescence images of human fibroblast
from a patient with RRAGD P88L and from a control patient in normal feeding (FED)
and upon amino acid starvation (AA STARV). Cells were stained with anti-TFEB and
anti-LAMP1. Scale bar, 10 μm. j Graph shows TFEB nuclear-cytosolic ratio intensity
during normal feeding and amino acids starved conditions (mean ± s.d. of n > 1000
cells from n = 3 independent experiments). Quantification performed as in (f).
Ordinary two-way ANOVA Sidak’s multiple comparison test (ns > 0.9, **p < 0.01).
canonical mTORC1 substrate, in cells overexpressing RagD mutants
(Fig. 3c, f). Finally, upon LLOMe or MK6-83 treatment, the expression
of TFEB target genes was blunted in RagD mutant-expressing cells
(Supplementary Fig. 4f, g), indicating a specific impairment of the
TFEB-mediated response to lysosomal damage.
To confirm these data in a more physiological and relevant cellular model, we generated human iPSC-derived cardiomyocytes
(hiPSC-CMs). Similarly to patient-derived fibroblasts, hiPSC-CMs
expressing RagD mutants showed impaired TFEB nuclear translocation both during amino acid starvation (Supplementary Fig. 5a) and
upon treatment with LLOMe (Fig. 3g, h and Supplementary Fig. 5b),
thus confirming the results obtained in HeLa and HK-2 cells.
Activation of TFEB during mitophagy through a PINK1- and Parkindependent mechanism34 is pivotal for kidney resistance to stress
stimuli35, as well as for mitochondrial quality control in cardiomyocytes under stress36. The expression of RagD mutants in HK-2 renal
cells treated with mitophagy-inducing agents, such as the mitochondrial electron transport chain inhibitors oligomycin and antimycin A
(oligomycin/antimycin A [O/A]), which are known to trigger TFEB
nuclear translocation34, led to TFEB cytoplasmic retention (Fig. 4a, b
and Supplementary Fig. 5c, d). In addition, we observed a reduction of
mitophagy activation, as demonstrated by decreased Parkin mitochondrial translocation (Fig. 4c, d) and reduced PINK1 and Parkin
protein levels (Fig. 4e–g). This suggests that RagD mutations identified
in patients with kidney tubulopathy and cardiomyopathy impair TFEBmediated mitophagy activation.
phosphorylation of S6K in samples transfected with RagD mutants was
still turned off by starvation, similarly to control sample, whereas in the
sample transfected with active RagA mutant starvation had no effect
(see Fig. 4B of ref. 3). These results suggest that RagD mutants do not
cause constitutive mTORC1-mediated phosphorylation of S6K. Consistent with these findings, in the present study we show that RagD
mutants induce constitutive phosphorylation of TFEB and other MiTTFE factors, whereas they have no effect on mTORC1-mediated phosphorylation of S6K. The ability of RagD mutants to induce phosphorylation of TFEB without affecting the phosphorylation of S6K is in line
with recent studies, including our own, that demonstrated the presence of an mTORC1 substrate-specific pathway, which we named
“non-canonical mTORC1 signaling”4,12–14,32,33. Remarkably, in a recent
study we provided structural evidence of mTORC1 substrate
specificity15.
Importantly, constitutive phosphorylation of MiT/TFE factors
induced by RRAGD mutations leads to their cytoplasmic retention,
strongly suggesting that MiT/TFE inhibition is the main mechanism
underlying kidney tubulopathy and cardiomyopathy.
Moreover, these mutations also inhibited the lysosomal/autophagic response to lysosomal injury (LLOMe and MK6-83) and mitochondrial stress (O/A), underlining their biological relevance. A recent
study showed that TFEB-mediated autophagic response plays a crucial
role in CaOX-induced kidney damage33. Kidney stones, in particular
calcium oxalate (CaOx), are associated with oxidative stress, inflammation, and tissue injury37,38. Mitochondria are critical for normal
kidney function as they provide energy support to maintain ion
homeostasis and eliminate waste metabolites and environmental toxicants, including drugs39. These data suggest that the kidney tubulopathy observed in patients carrying RRAGD mutations may be due to
an impairment of the TFEB/TFE3-mediated autophagic response.
Moreover, the role of mitochondria is of particular importance in
the heart as they provide ATP through oxidative phosphorylation to
sustain contractile function. In pathological conditions, mitochondria
also represent the primary source of reactive oxygen species that
promote cardiomyocyte death and heart failure40. To protect against
mitochondrial damage, cardiomyocytes use well-coordinated quality
control mechanisms that maintain overall mitochondrial health
through mitochondrial biogenesis, mitochondrial dynamics, and
mitophagy40. Importantly, these quality control mechanisms are
regulated at the transcriptional level by TFEB41. Recent studies showed
that TFEB improves cardiomyocyte survival in several pathological
conditions. Adeno Associated Viral vectors (AVV)-mediated TFEB
overexpression was found to attenuate autophagic blockade, cardiomyocyte death, and heart failure in MAO-A transgenic mice42. Furthermore, it has been reported that loss of TFEB leads to cardiac
Discussion
We identified a novel family with multiple individuals affected by
kidney tubulopathy and cardiomyopathy syndrome and carry a
c.263 C > T (P88L) mutation in the RRAGD gene. Similarly to previously
described families with this disease3, the disease-causing mutation is
located in the nucleotide-binding region of RagD. In silico modeling of
the RagD mutant identified in this family, as well as the mutations
found in all previously described families, indicated that they suppress,
either directly or indirectly, GTP binding to RagD as demonstrated by
GTP binding and GTPase activity assays. Consequently, all RagD
mutated proteins are preferentially in the nucleotide-free state or GDP
conformation state, leading to constitutive activation of the protein.
In the original study, in which kidney tubulopathy and cardiomyopathy was first described by Schlingmann et al., the authors
claimed that the disease was caused by mTORC1 hyperactivation
induced by RRAGD mutations3. However, in that study the degree of
mTORC1 hyperactivity induced by RRAGD mutations (as measured
by S6K phosphorylation) was marginal and the effects were highly
variable among the different mutations. Most importantly, the
Nature Communications | (2023)14:2775
5
Article
****
2.5
+
-
+
-
****
+
kDa 72-
2.0
+
RagD-P88L
TFEB nuclear traslocation
(Int nucl/cyt)
Control
****
+
+
+
Bas
LLOMe
1.5
HA
1.0
TFEB
55-
0.5
72-
S6K
43-
Actin
LL
TFEB HA Gal3
p-S6K
72-
0.0
N
O T
M
R e
ag 1
R D h
ag W
D T
R S
ag 7
D 7
R P L
a 8
R gD 8 L
ag W
D
R ST
ag 7
D 7L
P8
8L
LLOMe
+
-
c
Hela WT
WT
b
HA-RagD-P88L
RagD-S77L
HA-RagD-S77L
RagD-P88L
empty
HA-RagD-WT
WT
Empty
empty
a
RagD-S77L
https://doi.org/10.1038/s41467-023-38428-2
LLOMe 1h
1.5
kDa
****
+
-
+
-
+
-
+
-
+
RagD-P88L
****
WT
Control
+
+
- Bas
+ MK6-83
72-
HA
1.0
TFEB
550.5
0.0
72-
p-S6K
72-
S6K
43-
Actin
M
K6 N T
R -83
ag 1
R D h
ag W
D T
R S
ag 7
7
R DP L
ag 8 8
R D L
ag W
D T
R S
ag 7
D 7L
P8
8L
MK6-83
****
2.0
RagD-S77L
Hela WT
HA-RagD-P88L
RagD-P88L
empty
HA-RagD-S77L
WT
HA-RagD-WT
TFEB nuclear traslocation
(Int nucl/cyt)
Empty
f
RagD-S77L
e
empty
d
TFEB HA
MK6-83 1h
g
h
RagD-WT
RagD-S76L
RagD-T97P
RagD-P88L
hiPSC-CMs
****
% TFEB nuclear signal/
total nuclei
LLOME 1h
150
TFEB
****
****
100
50
0
mRNA-RagD
WT
S76L T97P
P88L
LLOME 1h
ACTN2 Dapi
hiPSC-CMs
hypertrophy by blocking autophagic degradation of GATA4, a
transcription factor responsible for the upregulation of several
cardiac-specific fetal genes involved in cardiomyocyte growth43. Most
importantly, a previous study described a de novo S75Y gain-offunction mutation in RRAGC, a RRAGD paralogue, in a fetus with syndromic fetal dilated cardiomyopathy (DCM)44. The same RRAGC
mutation was introduced in a zebrafish model, which showed severe
cardiomyopathy. Remarkably, the phenotype was rescued by TFEB
overexpression31.
Despite the beneficial effect of TFEB in the context of RRAGC autoactivating mutations31, it has been shown that heart-specific TFEB
overexpression induces cardiomyopathy in transgenic mice45. On the
Nature Communications | (2023)14:2775
other hand, AAV-mediated moderate TFEB overexpression seems to
exert beneficial effects46. These studies suggest TFEB levels and subcellular localization may play a beneficial or detrimental role
depending on the physio-pathological context.
In conclusion, our data suggest that constitutive activation of
RagD causes inhibition of MiT/TFE activity, which causes defective
cellular metabolic responses to different stimuli, such as lysosomal or
mitochondrial damage. This can cause a cascade of pathological
changes that ultimately contribute to the onset of kidney tubulopathy
and cardiomyopathy and may be involved in additional disease entities. Currently, many different types of renal tubulopathies and cardiomyopathies are considered idiopathic1. Our data suggest these
6
Article
https://doi.org/10.1038/s41467-023-38428-2
Fig. 3 | RagD mutants impair TFEB response to lysosomal damaging agents.
a Representative immunofluorescence images of HeLa cells transfected with HARagD WT or mutants (S77L and P88L) and treated with 500 μM LLOMe (for 1 h).
Cells were stained with anti-TFEB and anti-HA. Staining for Galectin-3 (Gal3) was
shown to visualize lysosomal membrane permeabilization. Scale bar, 10 μm.
b Graph shows the TFEB nuclear-cytosolic ratio intensity of the HA positive (RagD
WT or mutants S77L, P88L) cells treated with LLOMe (mean ± s.d. of n > 1000 cells
from n = 3 independent experiments). Ordinary one-way ANOVA Tukey multiple
comparison test (****p < 0.0001). Quantification performed as in Fig. 2f. c Western
blot representing TFEB molecular weight shift, phospho-S6K and total S6K in HeLa
cells transfected with HA-RagD WT or mutants (S77L and P88L) followed by LLOMe
treatment (n = 3 independent experiments). d Representative immunofluorescence
images of HeLa cells transfected with Ha-RagD WT or mutants (S77L and P88L) and
treated with 30 μM MK6-83, a specific TRPML1 agonist, for 1 h. Cells were stained
with anti-TFEB and anti-HA. Scale bar, 10 μm. e Graph shows the TFEB nuclearcytosolic ratio intensity of the HA positive (RagD WT or mutants S77L, P88L) cells
treated with MK6-83 (mean ± s.d. of n > 1000 cells from n = 3 independent
experiments). Quantification performed as in Fig. 2f. Ordinary one-way ANOVA
Tukey multiple comparison test (****p < 0.0001). f Western blot representing TFEB
molecular weight shift, phospho-S6K and total S6K in HeLa cells transfected with
HA-RagD WT or mutants (S77L and P88L) followed by MK6-83 treatment (n = 3
independent experiments). g Representative immunofluorescence staining for
TFEB and sarcomeric marker ACTN2 in hiPSC-CMs transfected with mRNA-RagDWT or -RagD mutants S76L, P88L, and T97P. Nuclei are stained with DAPI. Scale bar,
50 µm. h Graph showing the percentage of cells with TFEB nuclear signal/total
nuclei in hiPSC-CMs transfected with mRNA-RagD-WT or -RagD mutants (S76L,
P88L, T97P). n = 10 areas from 2 independent wells; one-way ANOVA followed by
Tukey’s multiple comparisons test. Data are shown as mean ± SEM (****p < 0.0001).
“idiopathic” forms may be caused by mutations in genes, such as
RRAGD, involved in the regulation of the non-canonical mTORC1
pathway. Restoring MiT/TFE function, either by selectively inhibiting
their phosphorylation or by promoting their nuclear translocation,
may represent an effective therapeutic strategy for these conditions.
Clinical data collection
Methods
The methods used in this research comply with all ethical regulations.
In particular, for human samples, data collection and genetic analysis
were performed after obtaining informed consent to participate and
publish identifiable medical information from all the study participants. For children, written informed consent to participate and publish medical information was obtained from the legal guardian. For
isolation of patient-derived fibroblasts each patient signed an
informed consent before enrolling in this study. The study protocol
covering all of the work involving humans in this manuscript has been
approved by the Ethical Committee of the AUO policlinico Unicampania “Luigi Vanvitelli” (with the protocol number 7539).
Materials
The reagents used in this study were obtained from the following
sources: antibodies against phospho-p70 S6 kinase (Thr389) (1A5) (cat.
# 9206 − 1:1000), p70 S6 kinase (cat. # 9202 − 1:1000), human TFEB
(cat. # 4240 − 1:1000 WB/1:100 IF), TFEB-pS211 (E9S8N) (cat. # 37681
used at 1:1000 WB/1:100 IF), Parkin (cat # 2132 1:500 WB/1:200 IF);
PINK1 (D8G3) (cat # 6946 1:1000 WB), mTOR (7C10) (cat # 2983 1:200
IF), GPNMB (E4D7P) XP (cat #38313 1:1000 WB) were from Cell Signaling Technology; antibodies against GAPDH (6C5) (cat. no. sc-322331:15000 WB), LAMP1 (H4A3) (cat # sc 200-11 1:400 IF), Galectin-3 (M3/
38 sc-23938 1:800), 14-3-3 B-11 (sc-133232 1:1000) were from Santa
Cruz; Flag M2 (cat. # F1804 1:1000 WB), ACTN2 EA-53 (cat. # A7811
dilution 1:1000 IF) and actin AC-74 (# A2228 − 1:5000 WB) were from
Sigma-Aldrich; HA.11 epitope tag (cat. 901513 − 1:1000) was from Biolegend; HA clone 3F10 (ref. 1186 7423001 1:800 FACS); Anti-HA High
Affinity (ref.11867423001 1:500 IF) from Roche; Tomm20 clone 29 (cat
# 612278 1:800 IF) and p62 Clone 3 (cat # 610832 1:800 WB) came from
BD Biosciences. HRP-conjugated secondary antibodies for mouse (cat.
# 401215 - dilution 1:5000) and rabbit (cat. # 401315 - dilution 1:5000)
were from Calbiochem; donkey anti-rabbit IgG (H + L) Alexa Fluor 488
(cat. #A-21206 - dilution 1:500), Alexa Fluor 568 (cat. # A-10042 dilution 1:500), donkey anti-mouse IgG (H + L) Alexa Fluor 568 (cat.
# A-10037 − 1:500), Alexa Fluor 647 (cat. # A-31571 − 1:500), Alexa Fluor
594 (cat. # A-21203 − 1:500), donkey goat anti-goat IgG (H + L) Alexa
Fluor 647 (cat. # A-21447 − 1:500), donkey anti-rat IgG (H + L) Alexa
Fluor 647 (cat- #A21247 1:500) were from Thermo Fisher Scientific. The
chemicals used were Torin 1 (cat. No. 4247) from Tocris; protease
inhibitor cocktail (cat. no. P8340) and puromycin (cat. no. P9620) from
Sigma-Aldrich; and PhosSTOP phosphatase inhibitor cocktail tablets
(cat. no. 04906837001) from Roche.
Nature Communications | (2023)14:2775
Clinical and laboratory data were collected from medical charts.
Serum magnesium and potassium from patients affected by RRAGD
mutations were compared with non-affected family members (pedigree numbers). Normality distribution was checked by using the
Kolmogorov–Smirnov test and statistical analyses was carried out by
two-sided unpaired t-test. Data collection and genetic analysis were
performed after obtaining informed consent to publish identifiable
medical information from all the subjects. The study protocol has
been approved by the Ethical Committee of University of Campania
“Luigi Vanvitelli” and is in compliance with all relevant ethical
regulations.
Whole-exome sequencing (WES)
Written informed consent was obtained from the parents. Genomic
DNA was extracted from peripheral blood leukocytes using standard
protocols. For library preparation of single samples, we followed
the manufacturer’s instructions (SureSelectQXT Automated Target
Enrichment for the Illumina Platform, Protocol Version B0, November
2015, Agilent Technologies, Santa Clara, CA, USA). The WES of three
affected members (X7321, X7322, X7323) was enriched using the SureSelect Human All Exon v7. Enriched DNA was validated and quantified
by microfluidic analysis using the High Sensitivity D1000 ScreenTape
Assay (Agilent Technologies) and the 4200 TapeStation System.
Data analysis
The libraries were sequenced using the Illumina NovaSeq 6000 System
performing paired-end runs covering 2 × 150 nt (Illumina Inc., San
Diego, CA, USA). The generated sequences were analyzed using an inhouse pipeline47 designed to automate the analysis workflow, made up
of modules performing each step using the appropriate tools commercially available or developed in-house. The average coverage of the
target bases was 100x with 95.4% of the bases covered by at least
20 reads.
Variant detection, mutation annotation, and Sanger sequencing
of genomic DNA
Autosomal dominant inheritance mechanism was considered,
attention was focused on variants that were present at a minor allele
frequency of ≤0.001 in Genome Aggregation Database (gnomAD,
https://gnomad.broadinstitute.org), (dbSNP, https://www.ncbi.
nlm.nih.gov/snp/), Exome Aggregation Consortium (Exac, http://
exac.broadinstitute.org), ClinVar database (https://www.ncbi.nlm.
nih.gov/clinvar/) and in the internal database of ~5400 Italian subjects. All three probands showed a heterozygous missense variant in
the RRAGD gene (NM_021244.5): c.263 C > T (p.Pro88Leu) on chromosome 6: 90097195 (hg.19). This variant was not previously
reported in literature (LOVD, ClinVar, HGMD) and is absent in the
frequency databases (gnomAD or ExAC). The identified candidate
7
Article
https://doi.org/10.1038/s41467-023-38428-2
a
b
Empty
Crop
HA-RagD-WT
HA-RagD-S77L
HA-RagD-P88L
3
**
****
2
1
0
NT
O
Ra /A
g 3h
Ra D W
g
T
Ra D S
gD 77
Ra P 8 L
g 8
Ra D W L
gD T
Ra S
gD 77L
P8
8L
O/A
Control
TFEB nuclear traslocation
(Int nucl/cyt)
HK-2 WT
**
O/A 3h
TFEB Tomm20
c
TFEB HA
Empty
HA-RagD-WT
HA-RagD-S77L
d
HA-RagD-P88L
Parkin
Parkin
Tomm20
Tomm20
HA
HA
HA
Parkin
Parkin
Parkin
Tomm20
Tomm20
Tomm20
Tomm20
****
****
6.0
4.0
2.0
0
D
R
ag
ag
R
R
D
W
O/A
Parkin
8.0
T
S7
7
ag
D L
P8
8L
HA
HA
HA positive cells containing
mito-Parkin colocalization
Control
HK-2 WT
HA
O/A 6h
1.5
PINK/Actin
***
Bas + + + + - - - O/A 6h - - - - + + + +
1.0
**
**
1.5
g
**
Parkin/Actin
f
RagD-P88L
WT
RagD-S77L
RagD-S77L
empty
WT
e
RagD-P88L
empty
Tomm20 Parkin
*
0.5
*
*
**
1.0
0.5
kDa
PINK1
55-
Parkin
43-
Actin
0
0
O/A 6h
Em
p
R
ag ty
R D
ag W
R DS T
ag 7
D 7L
P8
8
Em L
pt
R
y
a
R gD
ag W
D
R S T
ag 7
D 7L
P8
8L
HA
Em
p
R
ag ty
R D
ag W
R DS T
ag 7
D 7L
P8
8
Em L
pt
R
y
a
R gD
ag W
R DS T
ag 7
D 7L
P8
8L
7272-
O/A 6h
Fig. 4 | RagD mutants impair TFEB response to mitochondrial injury.
a Representative immunofluorescence images of HK-2 cells transfected with HARagD WT or mutants (S77L or P88L) and treated with 10 μg/ml Oligomycin and
5 μg/ml Antimycin A (O/A) for 3 h. Cells were stained with anti-TFEB and anti-HA.
Staining for Tomm20 was used as mitochondrial marker. Scale bar, 10 μm. b Graph
shows the TFEB nuclear-cytosolic ratio intensity of the HA positive (RagD WT or
mutants S77L, P88L) cells treated with O/A (mean ± s.d. of n > 1000 cells from n = 3
independent experiments). Quantification performed as in Fig. 2f. Ordinary oneway ANOVA Tukey multiple comparison test (**p < 0.01, ****p < 0.0001).
c Representative immunofluorescence images of HK-2 cells transfected with HARagD WT or mutants (S77L or P88L) and treated with 10 μg/ml Oligomycin and
5 μg/ml Antimycin A (O/A) for 6 h. Cells were stained with anti-Parkin (Rabbit
polyclonal) and anti-HA (Rat monoclonal). Staining for Tomm20 (Mouse monoclonal) was used as a mitochondrial marker. Scale bar, 10 μm. d Graph shows the
mitochondria-Parkin co-localization of the HA positive (RagD WT or mutants S77L,
P88L) cells treated with O/A (mean ± s.d. for n = 195 cells of 3 independent
experiments). Ordinary one-way ANOVA Tukey multiple comparison test
(****p < 0.0001). e Representative western blot images showing: PINK1, Parkin, and
Actin in HK-2 cells transiently transfected with HA-RagD-WT or RagD mutants, S77L,
P88L, treated ± O/A for 6 h. Graphs show the PINK1/Actin (f) and Parkin/Actin ratios
(g). Data are representative of n = 3 biologically independent experiments. Ordinary one-way ANOVA Tukey multiple comparison test (*p < 0.05,
**p < 0.01, ***p < 0.001).
disease causing variant was confirmed in all affected members by
direct Sanger Sequencing using specific primers (RRAGD exon 2:
Forward 5’-TGGAAGAGTGGCATCATCTG-3’ Reverse 5’-CCATCA
TACCCCTGAGACTC-3’). Healthy members did not show this
variant.
Protein stability and ligand binding prediction
Nature Communications | (2023)14:2775
We used the MERSi algorithm from Molsoft ICM-Pro 3.8-6a (Molsoft,
San Diego, CA, USA) to predict the effect of the missense mutations in
RagD on protein stability and protein nucleotide binding48. The effect
of the individual mutations was analyzed using the PDB model of RagD
8
Article
GTP with the reference code 2q3f. To calculate the stability change, the
algorithm takes into consideration a comprehensive set of free-energy
contributions, represented under the formula Δ/ΔG = ΔGmutant −
ΔGWT. The residue-specific constants that account for the free energies of the different states were previously derived empirically using a
large set of experimental data48. Each mutation was followed up by
Monte Carlo simulations49 for that particular residue and surrounding
residues. Other areas of the protein are considered rigid for the purpose of this analysis. A positive energy value indicates that the mutation is likely to be destabilizing. Since no structural model is currently
available for RagD GDP, we used the RagC GDP, PDB 6CES to estimate
the effect of the mutations in the diphosphate-loaded form of the
protein. The binding free energy change (Δ/ΔG binding) was determined as the difference between the binding free energy of the mutant
and wild-type proteins. As for the stability analysis, Monte Carlo
simulations were performed to account for structure relaxation.
Modeling the missense mutations in RagD
Structural models of the mutations in RagD were prepared using RagD
GTP (PDB code 2q3f). Mutations were introduced using ICM-Pro 3.8-6a
(Molsoft, San Diego, CA, USA) with local minimization to optimize side
chain positions in the vicinity of the mutation site.
Protein purification
Variants of recombinant GST-RagD (WT, S76L, P88L, T97P, P119R, and
I221K) were expressed from pET24d(+) plasmid (Novagen) in E. coli
Rosetta (DE3) cells (Novagen). Protein expression was induced with
1 mM IPTG overnight at 16 °C. The bacteria were disrupted by sonication in lysis buffer [50 mM Tris-Cl (pH 7.5), 200 mM NaCl, 5% glycerol,
1 mM DTT, 1x complete EDTA free protease inhibitor cocktail (Roche),
and 0.1% Nonidet P40], and the clarified lysates were incubated at 4 °C
for 1 h with Glutathione Sepharose 4B (GE Healthcare). The resin was
then washed three times with lysis buffer and bound GST- RagD variants were eluted with 10 mM reduced glutathione, 50 mM Tris-Cl
(pH 7.5), and 10% glycerol. The purified protein samples were analyzed
by SDS-PAGE and Coomassie blue staining, and stored at −80 °C.
GTP-binding assay
In GTP-binding assays19, increasing concentrations (from 31.25 nM to
2 μM) of recombinant GST-RagD variants were incubated with 1 nM
α-32P-GTP (Hartmann Analytics) for 4 h at 4 °C in 50 mM HEPES (pH
7.5), 100 mM potassium acetate, 2 mM MgCl2, 2 mM DTT, and 0.1%
CHAPS. The samples were then spotted onto a chilled metal block
covered with Parafilm and to induce crosslinking, UV light of a total
energy of 300 mJ was applied using GS Gene Linker (Bio-Rad). The
samples were then mixed with Laemmli buffer, denatured for 10 min at
65 °C, and run on 7.5% SDS-PAGE gels that were then dried and analyzed by autoradiography.
GTP hydrolysis assays
100 nM of purified GTPase were incubated for 3 h at room temperature
in reaction buffer (20 mM Tris-HCl [pH 8.0], 2 mM EDTA, and 1 mM
DTT, 20 mM MgCl2) containing 40 nM [α-32P]-GTP (Hartman Analytic;
3,000 Ci/mmol). Reactions of 10 mL were stopped by the addition of
3 µL stop buffer (1% SDS, 25 mM EDTA, 5 mM GDP, and 5 µM GTP),
samples were then denatured for 4 min at 65 °C, and 5 µL of each
sample were loaded onto PEI Cellulose F Plates (Merck). Thin-layer
chromatography was performed with buffer containing 1.0 M acetic
acid and 0.8 M LiCl. Results were visualized using a phosphorimager
and quantified with ImageJ software.
Plasmids
pRK5-HA-GST-RagD wt (#19307) and pRK5-HA-GST-RagD S77L
(#19308) were a kind gift from D. Sabatini (Addgene plasmids). The
plasmids carrying the human mutations: pRK5- HA-GST-RagD P88L,
Nature Communications | (2023)14:2775
https://doi.org/10.1038/s41467-023-38428-2
pRK5-HA-GST-RagD S76L, pRK5-HA-GST-RagD S76W, pRK5-HA-GSTRagD P119L, pRK5-HA-GST-RagD P119R, pRK5-HA-GST-RagD I221K,
pRK5-HA-GST-RagD T97P were generated using the QuikChange II-E
Site-Directed Mutagenesis Kit (no. 200555, Agilent Technologies).
pTRIP-GPNMBprom-NUC-mCherry was generated by synthesis of the
GPNMB promoter region sequence (448 bp) flanked by NdeI and NheI
restriction enzyme sequences. The fragment was cloned into a lentiviral vector NUC-mCherry-pTRIP plasmid (was a gift from Thomas
Weber Addgene cat. No. 163520) changing the CMV promoter
sequence with the GPNMB promoter sequence between the NdeI and
NheI restriction sites.
Generation of HeLa FLCN KO and HK-2 FLCN KO cell lines
HeLa (ATCC CCL/2) FLCN knockout cells were generated using the allin-one CRISPR/Cas9 vector system obtained from Merck. The gRNA
sequence was 5’-TGTCAGCGATGTCAGCGAG-3’. A single plasmid containing the Cas9-GFP and the gRNA was transfected using the LipoLTX
reagent (cat no. 94756 Thermofisher) following the manufacturer’s
instructions. 48 h after transfection, GFP-positive cells were sorted into
single cells via FACS. Clones were analyzed by Sanger sequencing and
the clones with homozygous indel mutations were expanded. HK-2
(ATCC CRL-2190) FLCN knockout cells were generated by CRISPr/Cas9
using the gRNA 5’-GGCACCATGAATGCCATCG-3’. Single-cell clones
carrying the INDEL mutations were genotyped by PCR reaction with
the specific primers: UP 5’-CTGCCTCCTCTGGTCATTCC-3’ and DOWN
5’-CTCGCACATGTCCGACTTTT-3’. PCR products were analyzed by
DNA Sanger sequencing and the cell clone carrying the compound
heterozygous deletion introducing a PSC: c.7 DEL CCATCGTG/
c.17DELGCAGGCCTGTTGCAGTCTCCAAGGCACCATGAATGCCATCGT
GGCTCTCTGCCAC was selected and expanded.
Cell cultures
Cells were cultured in the following media: HeLa (ATCC CCL/2) and
HeLa FLCN KO in MEM (cat. no. ECB2071L, Euroclone); HEK293T (CRL3216) in DMEM high glucose (cat. no. ECM0728L, Euroclone); HK-2
(ATCC CRL-2190), HK-2 FLCN KO in DMEM-F12 (cat. no. 11320033,
Thermo Fisher Scientific). All media were supplemented with 10%
inactivated FBS (cat. no. ECS0180L, Euroclone), 2 mM glutamine (cat.
no. ECB3000D, Euroclone), penicillin (100 IU/ml), and streptomycin
(100 μg/ml) (cat. no. ECB3001D, Euroclone) and maintained at 37 °C
and 5% CO2. HeLa FLCN KO and HK-2 FLCN KO cells with inducible
expression of TFEB-GFP were generated upon transduction of these
cells with pLVX-TETONE-GFP-TFEB inducible lentiviral plasmids. HeLa
FLCN KO GPNMBprom-NUC-mCherry were generated upon transduction of these cells with the pTRIP-GPNMBprom-NUC-mCherry plasmid.
Cells were selected using 1 μg/ml of puromycin and then FACS sorted.
All cell lines were purchased from ATCC, validated by morphological
analysis, and routinely tested for the absence of mycoplasma. Fibroblasts from RRAGD P88L patients and healthy subjects were cultured in
DMEM high glucose supplemented with 20% inactivated FBS, 2 mM
glutamine, penicillin (100 IU/ml), and streptomycin (100 μg/ml) and
maintained at 37 °C and 5% CO2.
Culture of human pluripotent stems and in vitro differentiation
into cardiomyocytes
Human induced pluripotent stem cells (hiPSCs) LUMC0020iCTRL-06
line
registered
at
(https://hpscreg.eu/cell-line/LUMCi028-A
and derived from skin fibroblasts of a healthy female individual
after informed consent and following approval from the Leiden
University Medical Center committee50) were cultured as previously
described51,52. Briefly, hiPSCs were seeded on vitronectin recombinant human protein and cultured in E8 medium; cells were passaged
twice a week using PBS containing EDTA 0.5 mM. RevitaCell Supplement (1:200) was added during passaging (all from Thermo Fisher
Scientific).
9
Article
Differentiation into cardiomyocytes (hiPSC-CMs) was induced in
monolayer as previously described51,52. Briefly, 2.5 × 104 cells per cm2
were seeded on growth factor-reduced Matrigel (Corning)-coated
plates. 24 h after plating, cardiac mesoderm induction was established
by culturing the cells in LI-BPEL medium supplemented with a mixture
of cytokines (20 ng/mL BMP4, R&D; 20 ng/mL Activin A, Miltenyi
Biotec) and the GSK3 inhibitor CHIR99021 (1.5 μmol/L, Axon Medchem). After 72 h, cytokines were removed and the Wnt inhibitor
XAV939 (5 mM, Tocris) was added for 72 h. LI-BPEL medium was further refreshed every 3–4 days.
Cell culture treatments
For drug treatment experiments, cells were incubated in a medium
containing one or more of the following compounds: LLOMe methyl
ester hydrobromide was purchased from Santa Cruz (Cat no. sc285992). Cells were treated with 500 μM LLOMe for 1 h or 6 h and
collected for immunofluorescence and WB. MK6-83 was purchased
from Tocris Bioscience (cat no. 5547). Cells were treated with 30 μM
MK6-83 for 1 h or 6 h and collected for immunofluorescence and WB.
Cells were treated with a mixture of 10 μg/ml Oligomycin (cat no. CAS
1404-19-9 EMD Millipore) and 5 μg/ml Antimycin A (cat no. 1397-94-0
Sigma-Aldrich) (O/A) for 3 h or 6 h and collected for immunofluorescence and WB, respectively. For experiments involving amino
acid starvation, cells were rinsed twice with PBS and incubated for 1 h
(6 h only for hiPSC-CMs experiments) in amino acid-free RPMI (cat. no.
R9010-01, US Biological) supplemented with 10% dialyzed FBS. For
amino acid refeeding, cells were re-stimulated for 45 min with 1× watersolubilized mix of essential (cat. no. 11130036, Thermo Fisher Scientific) and non-essential (cat. no. 11140035, Thermo Fisher Scientific)
amino acids resuspended in amino-acid-free RPMI supplemented with
10% dialyzed FBS, plus glutamine.
Western blot
Cells were rinsed once with PBS and lysed in ice-cold lysis buffer
(250 mM NaCl, 1% Triton, 25 mM Hepes pH 7.4). Directly before use,
protease/phosphatase inhibitors (Thermo Fisher Scientific) were
added to the lysis buffer. Total lysates were passed 10 times through a
25-gauge needle with syringe, kept at 4 °C for 10 min and then cleared
by centrifugation in a microcentrifuge (18,800 × g at 4 °C for 10 min).
Protein concentration was measured by BCA assay (Cat no. 23225
Thermo Scientific). Cell lysates were resolved on SDS- polyacrylamide
gel electrophoresis on 4–12% Bis-Tris gradient gels (cat. no. MP41G15
mPage Bis-Tris Precast gels, Millipore) then transferred to PVDF
membranes (Millipore Corp ref IPVH00010). Membranes were incubated with primary antibodies overnight at 4 °C and with secondary
antibodies for 1 h at RT. Quantification of western blotting was performed by calculating the intensity of phosphorylated and total proteins by densitometry analysis using the Fiji software. The ratios
between phosphorylated and total protein values were normalized to a
control condition for each experiment.
Immunoprecipitation
HeLa FLCN KO cells were transfected with TFEB-FLAG in combination
with RagD-HA-GST WT and mutants and RagA-HA-GST. 48 h following
transfection, cells were rinsed twice with ice-cold PBS and lysed with
NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5% NP-40,
one tablet of phosphatase inhibitor cocktail (PhosphoSTOP cat. no.
04906837001) per 10 ml of buffer and protease inhibitor (P8340
SIGMA). The lysates were cleared by centrifugation at 18,800 × g at
4 °C in a microcentrifuge for 10 min. Protein concentration was analyzed by Bradford assay (BIORAD Cat no #5000006). For immunoprecipitation, the FLAG M2 (A2220 Sigma) beads were pre-equilibrated
in NP-40 lysis buffer and then added to cleared lysates and incubated
at 4 °C for 2 h. After immunoprecipitation, the beads were washed
three times with wash buffer (50 mM Tris-HCl pH 7.5, 0.2% NP-40,
Nature Communications | (2023)14:2775
https://doi.org/10.1038/s41467-023-38428-2
50 mM NaCl) supplemented with protease and phosphatase inhibitors.
Immunoprecipitated proteins were denatured by the addition of
Laemmli buffer, heated at 95 °C for 10 min, and centrifugated at max
speed for 5 min. Immunoprecipitated and input samples were resolved
by SDS-polyacrylamide gel electrophoresis on 4–12% Bis-Tris gradient
gels (cat. no. MP41G15 mPage Bis-Tris Precast gels, Millipore) and
analyzed by immunoblotting with the indicated primary antibodies.
For endogenous IP, HeLa FLCN KO cells were transfected with
RagD-HA-GST WT and mutants in combination with RagA-HA-GST.
48 h following transfection cells were crosslinked using DSP (Cat. no
22585 Thermofisher Scientific) and lysed with RIPA lysis buffer (HEPES
40 mM pH 7.4, EDTA 2 mM, 1% Na-Deoxycholate, 1% NP-40, 0.1% SDS,
10 mM Na4-Pyrophosphate, 10 mM Na2-Glycerophosphate, 1X protease inhibitors. The lysates were cleared by centrifugation at
18,800 × g at 4 °C in a microcentrifuge for 10 min. Protein concentration was analyzed by Bradford assay. For immunoprecipitation, the HA
beads (Thermofisher Scientific ref 26182) were pre-equilibrated in RIPA
lysis buffer and then added to cleared lysates and incubated at 4 °C
overnight. After immunoprecipitation, the beads were washed three
times with RIPA buffer supplemented with 250 mM NaCl and immunoprecipitated proteins were denatured and resolved by Western blot.
FACS processing and GPNMB fluorescent reporter activity
To measure the GPNMB promoter activity, HeLa FLCN KO cells carrying
the GPNMBprom-NUC-mCherry were transfected with appropriate
RagD constructs for 48 h and then processed for FACS analysis. Cells
were trypsinized and fixed in Fix/Perm Buffer (cat no. 51-9008100 BD
Biosciences) for 10 min at 37 °C. Cells were pelleted at 0.4 × g for 5 min
and washed with Perm/Wash buffer (cat no. 51-9008102 BD Biosciences). Then, cells were permeabilized with Perm/Wash buffer for
30 min on ice and then for 30 min at RT. After permeabilization, cells
were incubated with anti-HA (clone 3F10 ref. 11867423001 Roche 1:800
FACS) primary antibody overnight at 4 °C to isolate the HA-RagD
positive cells. Upon staining, cells were washed three times and incubated with anti-rat secondary antibody (Alexa Fluor 488 cat no. A11006
1:500 Thermo Fisher Scientific) for 1 h at RT. Then cells were washed
three times and resuspended in FACS buffer (2 mM EDTA, 2% FBS
diluted in PBS). The fluorescent intensities were analyzed by FACS
(FACS ARIA III BD biosciences).
RNA extraction, reverse transcription, and quantitative PCR
RNA samples from cells were obtained using the RNeasy kit (Cat no.
74134 Qiagen). according to the manufacturer’s instructions. cDNA
was synthesized using QuantiTect Reverse Transcription kit (Cat no.
205314 Qiagen). Real-time quantitative RT-PCR on cDNAs was carried
out with the LightCycler 480 SYBR Green I mix (Cat no. 04887352001
Roche) using the Light Cycler 480 II detection system (Roche) with the
following conditions: 95 °C, 5 min (95 °C, 10 s; 60 °C, 10 s; 72 °C,
15 s) × 40. Fold change values were calculated using the ΔΔCt method.
In brief, an internal control (HPRT1) was used as a ‘normalizer’ to calculate the ΔCt value. Next, the ΔΔCt value was calculated between the
‘control’ group and the ‘experimental’ group. Finally, the fold change
was calculated using 2(−ΔΔCt). Biological replicates were grouped in
the calculation of the fold-change values. For TFEB targets gene analysis HeLa FLCN KO cells were co-transfected with either RagD mutants
constructs and EGFP empty vector using the Fugene reagent (cat no.
E2312 Promega) following the manufacturer’s instructions. 48 h upon
transfection, GFP-positive cells were sorted via FACS and RNA was
extracted for the subsequent analysis.
Immunofluorescence and image quantification
For immunofluorescence, the following antibodies were used: TFEB
(Cell Signaling cat. 4240S 1:200), Phospho-TFEB (Ser211) (Cell Signaling cat. 37681 1:200), HA.11 clone 16B12 (BioLegend 901501 1:500)
Parkin (Cell Signaling cat 2132 1:200), Tomm20 (BD cat n 612278
10
Article
https://doi.org/10.1038/s41467-023-38428-2
Nuclei were counterstained with DAPI (all Thermo Fisher Scientific).
Images were acquired with a Leica SP8 WLL confocal laser-scanning
microscope using ×63 magnification objective and Z stack acquisition.
1:800), Galectin-3 (M3/38 sc-23938 1:800) already described above.
Cells were fixed in PFA 4% for 10 min and permeabilized with saponin
blocking buffer whereas for TFEB immunostaining cells were permeabilized in 0.1% (w/v) Triton X-100, 1% (w/v) horse serum, and 1% (w/
v) BSA in PBS. Cells were incubated with the indicated primary antibodies overnight and subsequently incubated with secondary antibodies for 1 h (AlexaFluor 488, AlexaFluor 568, AlexaFluor 647 all
Thermo Fisher 1:400). For confocal imaging, the samples were examined under a Zeiss LSM 800 confocal microscope. Optical sections
were obtained under a ×63 immersion objective at a definition of
1024 × 1024 pixels, adjusting the pinhole diameter to 1 Airy unit for
each emission channel to have all the intensity values between 1 and
254 (linear range). The microscope was operated on the Zeiss Zen blue
2.1 software platform (Carl Zeiss). For image analysis, the images were
acquired with an automated confocal microscopy (Opera System,
Perkin-Elmer) and analyzed through Columbus Image Data Storage
and Analysis System (Perkin-Elmer, Waltham, MA, USA) by the High
Content Screen (HCS) Facility at Tigem (Opera Phenix HCS system,
Perkin-Elmer). A dedicated script was applied, as previously reported53,
to evaluate TFEB nuclear translocation and mTORC1/Lamp1 colocalization. At least three independent experiments, and up to
3000 individual cells per treatment from at least two independent
wells, were routinely analyzed. P values were calculated on the basis of
mean values from independent wells. The data are represented by the
percentage of nuclear translocation versus the indicated control using
Excel (Microsoft) or Prism software (GraphPad software).
Lentiviruses were produced by transfection of HEK293T cells with
pLVX-EIF1α-HA-GST- RagD-WT, pLVX-EIF1α-HA-GST-RagD-P88L and
pLVX-EIF1α-HA-GST-RagD-S76L, constructs in combination with the
psPAX2 [Addgene, #12260], pMD2G/VSVG [Addgene, #12259] packaging plasmids using Lipofectamine LTX transfection reagent (Invitrogen). Five hours after transfection, the medium was changed to DMEM
supplemented with 10% FBS. Forty-eight hours later, virus-containing
supernatants were collected, passed through a 0.45-μm filter to eliminate cell debris. hiPSCs (CBiPS1sv-4F-40, derived from cord blood of a
neonatal female individual, registered at https://hpscreg.eu/cell-line/
ESi007-A and supplied by EBiSC-European bank for induced pluripotent stem cells https://ebisc.org/ESi007-A) were cultured on human
recombinant truncated vitronectin protein and cultured in E8
medium; cells were passaged twice a week with PBS containing
EDTA 0.5 mM.
Cells were then differentiated into cardiomyocytes using the
STEMdiff Cardiomyocyte Differentiation Kit (Stem Cell Technologies, #05010) and subjected to lentiviral infection (Multiplicity Of
Infection: 3) at Day 13 (beating appeared at day 8) of differentiation
in the presence of 8 μg/ml polybrene (cat. no. tr-1003-G, EMD
Millipore).
In vitro generation of RagD mRNA and transfection
Statistical analysis
RagD-WT and RagD mutants (S76L, P88L, T97P) sequences were
ordered as a gBlock (IDT), including the T7 promoter, HA-tag, target
sequence, T2A self-cleaving peptide sequence and mCherry, and
cloned into the pMiniT 2.0 vector using the NEB PCR Cloning Kit (New
England Biolabs) according to the manufacturer’s instructions. The
target gBlock sequences were amplified by PCR using Platinum Taq
DNA polymerase (Thermofisher Scientific) and the primers provided
by the NEB PCR Cloning Kit (New England Biolabs). The PCR products
were purified and subsequently digested with XhoI restriction enzyme
and run on a 1% agarose TBE gel. The specific band was extracted using
the Wizard SV Gel and PCR Clean-Up System (Promega) and used as a
template for in vitro transcription.
RagD-WT and RagD mutants (S76L, P88L, T97P) mRNAs were
generated by in vitro transcription using INCOGNITO T7 5mC- and ΨRNA Transcription Kit, ScriptCap Cap 1 Capping System and A-Plus
Poly(A) Polymerase Tailing Kit (all from Cellscript, LLC) following the
manufacturer’s instructions. hiPSC-CMs were transfected with RagDWT or RagD mutants mRNAs using Lipofectamine Stem Transfection
Reagent (Invitrogen) according to the manufacturer’s instructions. For
transfection, 250 ng of the mRNA per 50,000 cells was mixed with
Opti-MEM (Gibco) and 0.5 μl Lipofectamine Stem Transfection
Reagent in a total volume of 15 μl and incubated for 10 min at RT before
being added drop-wise to the cells. The cells were refreshed 18–20 h
after transfection. The day after, hiPSC- CMs were treated with 500 μM
LLOMe for 1 h and collected for immunofluorescence.
The experiments were repeated at least three times, unless stated
otherwise. As indicated in the figure legends, all quantitative data are
presented as the mean ± s.d. or SEM of biologically independent
experiments or samples. For each experiment we described specific
statistic test used and the relative significance in the figure
legend. Statistical analyses were performed using GraphPad Prism 8.0.
For Real Time experiments, a script for linear regression was designed
and used in R software for qpcR (version 1.4-1).
Immunofluorescence analysis of hiPSC-CMs
2.
HiPSC-CMs were fixed with 4% PFA in PBS for 10 min and permeabilised
with PBS/0.1% Triton-X-100 for 7 min at room temperature. The cells
were then blocked in blocking solution containing PBS/1% BSA for 1 h
at room temperature and incubated overnight at 4 °C with anti-alpha
sarcomeric actinin (ACTN2 mouse monoclonal, Sigma‐Aldrich #A7811,
dilution 1:1000) and anti-TFEB (rabbit polyclonal, Cell Signaling
#4240S, dilution 1:200). After washing, hiPSC-CMs were incubated for
1 h at room temperature in the dark with the appropriate
fluorochrome-conjugated secondary antibody Donkey anti-Rabbit
Alexa Fluor 488 (1:300) and Donkey-anti-mouse AF594 (1:300).
Nature Communications | (2023)14:2775
Mammalian lentiviral production and hiPSC-CMs transduction
Reporting summary
Further information on research design is available in the Nature
Portfolio Reporting Summary linked to this article.
Data availability
Full scans for all western blots as well as raw data for all the graphs are
provided with this manuscript as Supplementary Fig. 6 and Source
data file, respectively. For graphs, the exact p value for all the experiments is present in the Source data file. The Whole-Exome Sequencing
(WES) data are deposited in Sequence Read Archive (SRA) of NCBI
repository (BioProject ID: PRJNA960632, available at the following
link). All other data are available from the corresponding author on
request. Source data are provided with this paper.
References
1.
3.
4.
5.
Iancu, D. & Ashton, E. Inherited renal tubulopathies-challenges and
controversies. Genes 11, 277 (2020).
Martinez, H. R., Beasley, G. S., Miller, N., Goldberg, J. F. & Jefferies, J.
L. Clinical insights into heritable cardiomyopathies. Front. Genet. 12,
663450 (2021).
Schlingmann, K. P. et al. mTOR-activating mutations in RRAGD are
causative for kidney tubulopathy and cardiomyopathy. J. Am. Soc.
Nephrol. 32, 2885–2899 (2021).
Napolitano, G. et al. A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube syndrome. Nature 585, 597–602 (2020).
Tsun, Z. Y. et al. The folliculin tumor suppressor is a GAP for the
RagC/D GTPases that signal amino acid levels to mTORC1. Mol. Cell
52, 495–505 (2013).
11
Article
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Sancak, Y. et al. Ragulator-Rag complex targets mTORC1 to the
lysosomal surface and is necessary for its activation by amino acids.
Cell 141, 290–303 (2010).
Nicastro, R., Sardu, A., Panchaud, N. & De Virgilio, C. The architecture of the Rag GTPase signaling network. Biomolecules 7,
48 (2017).
Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).
Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino
acid signaling to mTORC1. Science 320, 1496–1501 (2008).
Sardiello, M. et al. A gene network regulating lysosomal biogenesis
and function. Science 325, 473–477 (2009).
Settembre, C. et al. TFEB links autophagy to lysosomal biogenesis.
Science 332, 1429–1433 (2011).
Li, K. et al. Folliculin promotes substrate-selective mTORC1 activity
by activating RagC to recruit TFE3. PLoS Biol. 20, e3001594 (2022).
Lawrence, R. E. et al. Structural mechanism of a Rag GTPase activation checkpoint by the lysosomal folliculin complex. Science
366, 971–977 (2019).
Napolitano, G., Di Malta, C. & Ballabio, A. Non-canonical
mTORC1 signaling at the lysosome. Trends Cell Biol. 32,
920–931 (2022).
Cui, Z. et al. Structure of the lysosomal mTORC1-TFEB-RagRagulator megacomplex. Nature 614, 572–579 (2023).
Vetter, I. R. & Wittinghofer, A. The guanine nucleotide-binding
switch in three dimensions. Science 294, 1299–1304 (2001).
Jeong, J. H. et al. Crystal structure of the Gtr1p(GTP)-Gtr2p(GDP)
protein complex reveals large structural rearrangements triggered
by GTP-to-GDP conversion. J. Biol. Chem. 287, 29648–29653 (2012).
Martina, J. A., Chen, Y., Gucek, M. & Puertollano, R. MTORC1 functions as a transcriptional regulator of autophagy by preventing
nuclear transport of TFEB. Autophagy 8, 903–914 (2012).
Shen, K., Choe, A. & Sabatini, D. M. Intersubunit crosstalk in the Rag
GTPase heterodimer enables mTORC1 to respond rapidly to amino
acid availability. Mol. Cell 68, 552–565.e8 (2017).
Martina, J. A. et al. The nutrient-responsive transcription factor TFE3
promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci. Signal 7, ra9 (2014).
Bronisz, A. et al. Microphthalmia-associated transcription factor
interactions with 14- 3-3 modulate differentiation of committed
myeloid precursors. Mol. Biol. Cell 17, 3897–3906 (2006).
Roczniak-Ferguson, A. et al. The transcription factor TFEB links
mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci. Signal 5, ra42 (2012).
Martina, J. A. & Puertollano, R. Rag GTPases mediate amino aciddependent recruitment of TFEB and MITF to lysosomes. J. Cell Biol.
200, 475–491 (2013).
Lang, M. et al. Clinical and molecular characterization of
microphthalmia-associated transcription factor (MITF)-related renal
cell carcinoma. Urology 149, 89–97 (2021).
Salles, D. C. et al. GPNMB expression identifies TSC1/2/mTORassociated and MiT family translocation-driven renal neoplasms.
J. Pathol. 257, 158–171 (2022).
Ballabio, A. & Bonifacino, J. S. Lysosomes as dynamic regulators of
cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol. 21,
101–118 (2020).
Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 19, 349–364 (2018).
Klionsky, D. J. et al. Autophagy in major human diseases. EMBO J.
40, e108863 (2021).
Napolitano, G. & Ballabio, A. TFEB at a glance. J. Cell Sci. 129,
2475–2481 (2016).
Zhang, W., Li, X., Wang, S., Chen, Y. & Liu, H. Regulation of TFEB
activity and its potential as a therapeutic target against kidney diseases. Cell Death Disco. 6, 32 (2020).
Nature Communications | (2023)14:2775
https://doi.org/10.1038/s41467-023-38428-2
31. Kim, M. et al. TFEB overexpression, Not mTOR inhibition, ameliorates RagC(S75Y) cardiomyopathy. Int. J. Mol. Sci. 22, 5494 (2021).
32. Goodwin, J. M. et al. GABARAP sequesters the FLCN-FNIP tumor
suppressor complex to couple autophagy with lysosomal biogenesis. Sci. Adv. 7, eabj2485 (2021).
33. Nakamura, S. et al. LC3 lipidation is essential for TFEB activation
during the lysosomal damage response to kidney injury. Nat. Cell
Biol. 22, 1252–1263 (2020).
34. Nezich, C. L., Wang, C., Fogel, A. I. & Youle, R. J. MiT/TFE transcription factors are activated during mitophagy downstream of
Parkin and Atg5. J. Cell Biol. 210, 435–450 (2015).
35. Lynch, M. R. et al. TFEB-driven lysosomal biogenesis is pivotal for
PGC1alpha-dependent renal stress resistance. JCI Insight 5,
e126749 (2019).
36. Ma, X. et al. Regulation of the transcription factor EB-PGC1alpha axis
by beclin-1 controls mitochondrial quality and cardiomyocyte death
under stress. Mol. Cell Biol. 35, 956–976 (2015).
37. Khan, S. R. Reactive oxygen species, inflammation and calcium
oxalate nephrolithiasis. Transl. Androl. Urol. 3, 256–276 (2014).
38. Khan, S. R. et al. Kidney stones. Nat. Rev. Dis. Prim. 2, 16008 (2016).
39. Zhang, X., Agborbesong, E. & Li, X. The role of mitochondria in acute
kidney injury and chronic kidney disease and its therapeutic
potential. Int. J. Mol. Sci. 22, 11253 (2021).
40. Vasquez-Trincado, C. et al. Mitochondrial dynamics, mitophagy and
cardiovascular disease. J. Physiol. 594, 509–525 (2016).
41. Lu, H., Sun, J., Hamblin, M. H., Chen, Y. E. & Fan, Y. Transcription
factor EB regulates cardiovascular homeostasis. EBioMedicine 63,
103207 (2021).
42. Santin, Y. et al. Oxidative stress by monoamine oxidase-A impairs
transcription factor EB activation and autophagosome clearance,
leading to cardiomyocyte necrosis and heart failure. Antioxid.
Redox Signal 25, 10–27 (2016).
43. Song, R. et al. TFEB insufficiency promotes cardiac hypertrophy by
blocking autophagic degradation of GATA4. J. Biol. Chem. 297,
101189 (2021).
44. Long, P. A. et al. De novo RRAGC mutation activates
mTORC1 signaling in syndromic fetal dilated cardiomyopathy.
Hum. Genet. 135, 909–917 (2016).
45. Kenny, H. C. et al. Cardiac specific overexpression of transcription
factor EB (TFEB) in normal hearts induces pathologic cardiac
hypertrophy and lethal cardiomyopathy. Preprint at bioRxiv https://
doi.org/10.1101/2021.02.16.431474 (2021).
46. Ma, X. et al. Transcription factor EB activation rescues advanced
alphaB-crystallin mutation-induced cardiomyopathy by normalizing desmin localization. J. Am. Heart Assoc. 8, e010866 (2019).
47. Musacchia, F. et al. VarGenius executes cohort-level DNA-seq variant calling and annotation and allows to manage the resulting
data through a PostgreSQL database. BMC Bioinforma. 19, 477
(2018).
48. Bordner, A. J. & Abagyan, R. A. Large-scale prediction of protein
geometry and stability changes for arbitrary single point mutations.
Proteins 57, 400–413 (2004).
49. Abagyan, R. & Totrov, M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides
and proteins. J. Mol. Biol. 235, 983–1002 (1994).
50. Zhang, M. et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome:
disease mechanisms and pharmacological rescue. Proc. Natl Acad.
Sci. USA 111, E5383–E5392 (2014).
51. Giacomelli, E. et al. Human-iPSC-derived cardiac stromal cells
enhance maturation in 3D cardiac microtissues and reveal noncardiomyocyte contributions to heart disease. Cell Stem Cell 26,
862–879.e11 (2020).
52. Campostrini, G. et al. Generation, functional analysis and applications of isogenic three-dimensional self-aggregating cardiac
12
Article
https://doi.org/10.1038/s41467-023-38428-2
microtissues from human pluripotent stem cells. Nat. Protoc. 16,
2213–2256 (2021).
53. Medina, D. L. et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat. Cell Biol. 17, 288–299
(2015).
of iPSC-CMs. G.P. and S.F. performed isolation of Pro88Leu patientderived fibroblasts. F.T. and C.R. performed patients data collection and
family pedigree. M.E.G.d.A. and L.A.H. performed and analyzed the in
silico modeling of RagD protein structure. I.S., M.F., and A.B. wrote the
manuscript. A.B. supervised the study.
Acknowledgements
Competing interests
We are grateful to Drs. Gennaro Napolitano, Chiara Di Malta, Graciana
Diez-Roux, Carmine Settembre for helpful suggestions and for the critical reading of the manuscript. We also thank Malika Jaquenoud for
technical assistance. We also want to thank the High Content Screening
(HCS) Facility of Tigem and Lucia Perone from Cell Culturing Core of
Tigem for technical assistance. We thank Rosaria Tuzzi for technical
assistance during isolation of Pro88Leu patient-derived fibroblasts. We
thank Eugenio del Prete from the Tigem Bioinformatic Core, for the
statistical analysis of Real Time PCR. We thank Luigi Ferrante for technical assistance during FACS analysis. We thank Dorien Ward-van
Oostwaard (Leiden University Medical Center, LUMC) for technical
support in hiPSC-CM differentiation and Sanne Wiersma (LUMC) for help
with mRNA in vitro transcription. We thank Cathal Wilson for the English
proofreading of the manuscript. This work was supported by the Italian
Telethon Foundation, European Research Council H2020 AdG (LYSOSOMICS 694282 to A.B.) Associazione Italiana per la Ricerca sul Cancro
A.I.R.C. (IG-22103 to A.B.), MIUR (PRIN 2017E5L5P3 and PRIN
202032AZT3 to A.B.), the Swiss National Science Foundation
(310030_184671 to C.D.V.), European Research Council (ERC-CoG
101001746 Mini-HEART to M.B.), and the Italian Telethon Foundation
(TGM22CBDM11 to L.S.).
A.B. is cofounder of CASMA Therapeutics, Inc, and Advisory board
member of Avilar andCoave Therapeutics and of Next Generation
Diagnostics. The remaining authors declare no competing interests.
Author contributions
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
I.S., M.F., and A.B. conceived the study. I.S. designed, performed, and
analyzed most of the experiments of immunofluorescences, WB, RTqPCR. M.F. performed the co-immunoprecipitations and generated and
characterized the GPNMBprom-mCherry reporter. N.Z. performed RagD
plasmids mutagenesis and virus and provided technical support to the
experiments. C.V. was involved in some immunofluorescence on FLCNknockout cells and generated Hela FLCN KO CRISPR–Cas9 gene-edited
cell line. L.D. and C.D.V. performed and analyzed the GTP-binding and
GTP-hydrolysis assay. F.D.V.B, A.T., and V.N. performed and analyzed the
WES and Sanger DNA sequencing from patients. J.M. generated HK-2
FLCN KO CRISPR–Cas9 gene-edited cell line and performed some
microscopy and FACS experiments. G.C. generated the RagD WT and
RagD mutants mRNAs. G.C. and V.M. performed and analyzed the
experiments on hiPSC-CMs. M.B. supervised hiPSC experiments. M.T.
and L.S. performed and analyzed the experiments on lentiviral infection
Additional information
Supplementary information The online version contains
supplementary material available at
https://doi.org/10.1038/s41467-023-38428-2.
Correspondence and requests for materials should be addressed to
Andrea Ballabio.
Peer review information Nature Communications thanks Zheng Ying
and the other, anonymous, reviewer(s) for their contribution to the peer
review of this work. A peer review file is available.
Reprints and permissions information is available at
http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
© The Author(s) 2023
1
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, (NA), Italy. 2Medical Genetics Unit, Department of Medical and Translational Science, Federico
II University, Naples, Italy. 3Leiden University Medical Center, 2333ZC Leiden, the Netherlands. 4Institute of Cell Biology, Biocenter, Medical University of
Innsbruck, Innsbruck, Austria. 5Department of Biology, University of Fribourg, CH-1700 Fribourg, Switzerland. 6Department of Precision Medicine, University
of Campania “Luigi Vanvitelli”, Naples, Italy. 7Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”, Naples, Italy. 8Institute for
Genetic and Biomedical Research, National Research Council (CNR), Milan, Italy. 9Department of Biology, University of Padua, 35131 Padua, Italy. 10Veneto
Institute of Molecular Medicine, 35129 Padua, Italy. 11Biogem Research Institute Ariano Irpino, Ariano Irpino, Italy. 12Department of Molecular and Human
Genetics, Baylor College of Medicine, Houston, TX, USA. 13Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital, Houston, TX, USA.
14
These authors contributed equally: Irene Sambri, Marco Ferniani.
e-mail: ballabio@tigem.it
Nature Communications | (2023)14:2775
13